Inflammatory Bowel Disease Plasma
Inflammatory Bowel Disease Plasma from IRB-consented donors with clinically confirmed IBD, a chronic immune-mediated inflammatory disease of the gut. Suitable for profiling TNF, IL-6 and IL-23/IL-17 pathway cytokines, gut permeability markers, and soluble biomarkers of disease activity and flare prediction. Crohn's versus ulcerative colitis stratification available.
Inflammatory Bowel Disease Plasma for Immune-Mediated Inflammatory Disease Research
Inflammatory Bowel Disease Plasma is collected from IRB-consented donors clinically diagnosed with inflammatory bowel disease (IBD) and processed within one day of collection to preserve cytokines, proteins and metabolites. IBD — comprising Crohn’s disease and ulcerative colitis — is a chronic immune-mediated inflammatory disease of the gastrointestinal tract in which a dysregulated mucosal immune response to the gut microbiota, on a permissive genetic background and with a compromised epithelial barrier, drives relapsing inflammation. Plasma is acellular and is supplied for soluble-analyte work rather than cell-based assays.
Mucosal Immune Dysregulation and Why Plasma
- TNF and IL-23/IL-17 axis signalling is central to IBD pathogenesis and is the target of the anti-TNF and anti-IL-23/IL-12 biologics that dominate current therapy, making these cytokines the highest-value plasma analytes.
- Gut-homing and leukocyte trafficking: the alpha4beta7 integrin-MAdCAM-1 axis and sphingosine-1-phosphate receptor signalling direct lymphocytes to the intestine and are targeted by vedolizumab and S1P modulators; soluble trafficking-related markers are measurable in plasma.
- Epithelial barrier dysfunction generates circulating permeability and epithelial-damage markers, providing a non-invasive window on mucosal integrity.
- Systemic inflammatory burden: CRP and other acute-phase reactants, IL-6, and neutrophil-derived mediators track disease activity and support flare-prediction research.
- Therapeutic drug monitoring and immunogenicity: biologic drug levels and anti-drug antibodies are measured in circulation, and this cohort supports assay development for that purpose.
- Fibrosis and stricturing biology in Crohn’s disease can be studied through extracellular matrix turnover markers in the same aliquot.
Donor Stratification Available
- Disease subtype: Crohn’s disease versus ulcerative colitis, and IBD-unclassified where documented
- Disease activity at collection: active flare versus clinical remission
- Disease location and extent: ileal, colonic or ileocolonic Crohn’s; proctitis, left-sided or extensive colitis
- Behaviour: inflammatory, stricturing, or penetrating/fistulising Crohn’s disease
- Treatment status: anti-TNF biologic, anti-IL-23/IL-12 biologic, anti-integrin biologic, JAK inhibitor, S1P modulator, thiopurine, corticosteroid, 5-ASA, or treatment-naive
- Surgical history, including prior resection or ostomy
- Extraintestinal manifestations and comorbidities such as primary sclerosing cholangitis, spondyloarthritis, or hidradenitis suppurativa
- Matched healthy controls available
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed inflammatory bowel disease donors
- Processed within one day of collection
- Anticoagulant selection available on request
- IRB-approved protocols and informed consent
- Custom aliquot volumes available upon request
De-identified Donor Data
- Verified inflammatory bowel disease diagnosis, with subtype where documented
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Disease activity and treatment context reported per lot where captured
- Additional IBD-specific metadata available on request
Applications
- TNF-alpha, IL-6, IL-23 and IL-17 pathway cytokine profiling
- Disease activity and flare-prediction biomarker discovery and validation
- Gut permeability and epithelial damage marker measurement
- Acute-phase reactant and systemic inflammation characterisation
- Biologic drug level and anti-drug antibody assay development
- Extracellular matrix turnover and intestinal fibrosis marker research
- Plasma proteomic and metabolomic discovery, including microbiota-derived metabolites
- Crohn’s versus ulcerative colitis differential biomarker studies and therapeutic response research
Other Inflammatory Bowel Disease Specimen Types
- Inflammatory Bowel Disease Serum
- Inflammatory Bowel Disease Bulk Plasma
- Inflammatory Bowel Disease Whole Blood
- Inflammatory Bowel Disease PBMC
- Inflammatory Bowel Disease Leukopak
- Isolated subsets: CD4+ T cells, CD8+ T cells, CD3+ T cells, CD19+ B cells, CD56+ NK cells
- Subtype-specific cohorts: Ulcerative Colitis Plasma, Crohn’s Disease Bulk Plasma
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Inflammatory bowel disease plasma is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare collection formats or check wider availability, visit our human plasma page.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.